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Background/aim: Thyroid disorders are associated with a wide variety of skin disorders that respond to treatment of hormone imbalance
in most cases and thus are of vital importance to dermatologists. This study aimed to evaluate skin findings associated with autoimmune
and nonautoimmune thyroid disease with respect to thyroid functional status and healthy controls.
Materials and methods: A total of 300 consecutive patients with either autoimmune (n = 173) or nonautoimmune (n = 127) thyroid
disease and 100 healthy control subjects were included in this cross-sectional study. Data on patient demographics, thyroid function
tests, and skin findings were recorded for patient and control groups.
Results: Compared to control subjects, patients had higher proportions in populations with alopecia (P < 0.001), nail thinning (P
= 0.02), brittle nails (P = 0.001), pruritus (P < 0.001), diffuse hyperhidrosis (P = 0.01), flushing (P = 0.001), and xerosis (P < 0.001).
Onycholysis (P = 0.02), yellow skin (P = 0.04), periorbital edema (P = 0.03), psoriasis (P = 0.001), and palmoplantar hyperkeratosis (P
= 0.007) were significantly more common in patients with autoimmune than nonautoimmune thyroid disease. A significantly higher
percentage of patients with autoimmune rather than nonautoimmune thyroid disease had overall skin findings (P = 0.03) among the
hyperthyroid patients.
Conclusions: Our findings indicate that the presence of skin findings in a majority of thyroid patients significantly differs for certain
cutaneous manifestations with respect to controls, autoimmune etiology, and thyroid functional status.
Key words: Skin findings, thyroid disease, autoimmune, thyroid status

1. Introduction
Thyroid hormone has an integral role in sustaining
normal epidermal functions including oxygen
consumption, protein synthesis, mitosis, differentiation,
and determination of layer thickness (1,2). Given that the
skin is often the first organ where a wide range of clinical
manifestations of thyroid hormone imbalance arises,
thyroid disease can often first be diagnosed by recognizing
cutaneous manifestations related to thyroid hormone
imbalance (2).
Hence, cutaneous manifestations of thyroid diseases
are of vital importance to dermatologists as they not only
signal the need of investigating and thus diagnosing an
underlying thyroid disorder but also they improve in most
cases with the treatment of thyroid disease (2,3).
* Correspondence: mumtaztakir@yahoo.com
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Autoimmune thyroid diseases are also of special
importance given that they are associated with other
organ-specific or systemic autoimmune disorders (4–6).
The present study was designed to evaluate skin
manifestations associated with autoimmune and
nonautoimmune thyroid disease with respect to thyroid
functional status and healthy controls.
2. Materials and methods
2.1. Study population
A total of 300 consecutive patients with either autoimmune
(n = 173, mean (SD) age: 42.0 (14.0) years; 93.6% were
female) or nonautoimmune (n = 127, mean (SD) age: 44.0
(10.0) years; 88.2% were females) thyroid disease and 100
healthy control subjects (mean (SD) age: 40.0 (13.0) years;
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90.0% were females) were included in this cross-sectional
study conducted at our outpatient clinic. Patients who were
diagnosed with only thyroid diseases and had not received
any treatment previously were included. The control group
consisted of healthy adults. Patients under 18 years of
age, patients with other known systemic and endocrine
diseases, and pregnant and lactating women were excluded
from the study.
Written informed consent was obtained from each
subject following a detailed explanation of the objectives
and protocol of the study, which was conducted in
accordance with the ethical principles stated in the
Declaration of Helsinki and approved by the institutional
ethics committee.
2.2. Assessments
Data on patient demographics, thyroid function tests
[serum levels for free triiodothyronine (T3), free
thyroxine (T4), thyroid stimulating hormone (TSH),
antithyroglobulin antibody, and antithyroid peroxidase
antibody), and examination of the integumentary system
(alopecia, hair dryness, nail thinning, onycholysis, pitting,
brittle nails, xerosis, pruritus, diffuse hyperhidrosis,
palmoplantar hyperhidrosis, facial erythema, flushing,
yellow skin, carotenemia, periorbital edema, diffuse edema,
palmoplantar hyperkeratosis, moist skin, vitiligo, alopecia
areata, psoriasis, urticarial, acne rosacea, contact dermatitis,
acanthosis nigricans, localized hyperpigmentation) were
recorded for patient and control groups as well as among
thyroid patients with respect to thyroid functional status.
Physical examinations of the patients were performed by
an endocrinologist. All subjects were examined for skin
findings or dermatoses by the same dermatologist.
2.3. Thyroid functional status
Patients were categorized as hyperthyroid, hypothyroid, or
euthyroid based on normal ranges defined for serum levels
for free T3 (1.71–3.71 pg/mL), free T4 (0.70–1.48 ng/mL),
TSH (0.35–4.94 IU/mL), antithyroglobulin antibody (0–34
IU/mL), and antithyroid peroxidase antibody (0–115 IU/
mL).
2.4. statistical analysis
Statistical analysis was conducted using computer
software (SPSS version 13.0, SPSS Inc., Chicago, IL, USA).
The chi-square test for the comparison of categorical
data and ANOVA and post hoc Tukey test were used
for the parametric variables. Data were expressed as
“mean (standard deviation; SD)” and percent (%) where
appropriate. P < 0.05 was considered statistically significant.
3. Results
3.1. Demographic and clinical characteristics
Our study group included 300 patients (274 females, 26
males) with thyroid disease, including 173 (58%) patients
with autoimmune thyroid disease and 127 (42.0%) with

nonautoimmune thyroid disease, and 100 control subjects
(90 females, 10 males). Patient and control groups were
homogeneous in terms of sex distribution, while patients
with nonautoimmune thyroid disease (mean (SD) age: 44.0
± 10.0 years) were older than patients with autoimmune
thyroid disease (42.0 ± 14.0 years) and control subjects
(40.0 ± 13.0 years) (P < 0.001 for each) (Table 1).
3.2. Skin findings with respect to autoimmunity
Skin findings were positive in 243 of 300 thyroid disease
patients (81.0%) and in 57 of 100 (57.0%) control subjects.
The most frequently observed skin findings were xerosis
in 135 patients (45.0%), alopecia in 97 (32.3%), pruritus
in 82 (27.3%), brittle nails in 66 (22.0%), nail thinning in
39 (13.0%), flushing in 43 (14.3%), and hair dryness in 27
patients (9.0%) (Table 1).
Among the population with at least one skin finding
(243 patients and 57 control subjects), 45.0% were patients
with autoimmune thyroid disease, 36.0% were patients
with nonautoimmune thyroid disease, and only 19.0%
were control subjects (P < 0.001). Specifically, patients
rather than control subjects had higher proportions
in populations with alopecia (54.2%, 36.4%, and 9.3%,
respectively, P < 0.001), nail thinning (61.7%, 21.3%,
and 17.0%, respectively, P = 0.02), brittle nails (60.8%,
28.4%, and 10.8%, respectively, P = 0.001), pruritus
(52.4%, 45.2%, and 2.4%, respectively, P < 0.001), diffuse
hyperhidrosis (58.1%, 34.9%, and 7.0%, respectively, P =
0.01), flushing (54.5%, 43.2%, and 2.3%, respectively, P =
0.001), and xerosis (43.7%, 45.7%, and 10.6%, respectively,
P < 0.001) along with a higher likelihood of autoimmune
than nonautoimmune thyroid patients to have these skin
findings except for xerosis (Table 1).
Onycholysis (80.0% vs. 20.0%, P = 0.02), yellow skin
(64.7% vs. 35.3%, P = 0.04), periorbital edema (75.0%
vs. 25.0%, P = 0.03), and psoriasis (91.7% vs. 8.3%, P =
0.001) were significantly more common in patients with
autoimmune than nonautoimmune thyroid disease, while
they were not observed in any of the control subjects.
All palmoplantar hyperkeratosis cases were observed in
patients with autoimmune thyroid disease (P = 0.007)
(Table 1).
3.3. Skin findings with respect to thyroid status
A total of 56 (18.7%) patients had hyperthyroidism, 158
(52.7%) patients had hypothyroidism, and 86 (28.7%)
patients had euthyroidism. Skin findings were observed
in 54 (96.4%), 135 (85.4%), and 77 (89.5%) patients
with hyperthyroid, hypothyroid, and euthyroid status,
respectively (Table 2).
A significantly higher percentage of patients with
autoimmune than nonautoimmune thyroid disease had
overall skin findings (70.3% vs. 29.7%, P = 0.03), alopecia
(84.6% vs. 15.4%, P = 0.01), and brittle nails (88.9% vs.
11.1%, P = 0.02) among hyperthyroid patients and had
nail thinning (90.9% vs. 9.1%, P = 0.01) and periorbital
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Table 1. Demographic and clinical characteristics and skin findings in study groups.
Control
(n = 100)

Autoimmune disease
(n = 173)

Nonautoimmune disease
(n = 127)

P-value

40.0 (13.0)

42.0 (14.0)

44.0 (10.0)

<0.001

Female

90 (90.0)

162 (93.6)

112 (88.2)

0.24

Male

10 (10)

11 (6.4)

15 (11.8)

At least one skin finding

57 (19.0)

135 (45.0)

108 (36.0)

<0.001

Alopecia

10 (9.3)

58 (54.2)

39 (36.4)

<0.001

Hair dryness

8 (22.9)

19 (54.3)

8 (22.9)

0.34

Nail thinning

8 (17.0)

29 (61.7)

10 (21.3)

0.02

Onycholysis

-

8 (80.0)

2 (20.0)

0.02

Pitting

-

2 (25.0)

6 (75.0)

0.47

Brittle nails

8 (10.8)

45 (60.8)

21 (28.4)

0.001

Xerosis

16 (10.6)

66 (43.7)

69 (45.7)

<0.001

Pruritus

2 (2.4)

44 (52.4)

38 (45.2)

<0.001

Diffuse hyperhidrosis

3 (7.0)

25 (58.1)

15 (34.9)

0.01

Palmoplantar hyperhidrosis

-

5 (41.7)

7 (58.3)

0.99

Facial erythema

5 (21.7)

10 (43.5)

8 (34.8)

0.91

Flushing

1 (2.3)

24 (54.5)

19 (43.2)

0.001

Yellow skin

-

11 (64.7)

6 (35.3)

0.04

Carotenemia

-

3 (27.5)

5 (62.5)

0.58

Periorbital edema

-

9 (75.0)

3 (25.0)

0.03

Diffuse edema

-

2 (28.6)

5 (71.4)

0.47

Palmoplantar hyperkeratosis

-

6 (100)

-

0.007

Moist skin

-

8 (66.7)

4 (33.3)

0.14

Vitiligo

-

2 (50)

2 (50)

0.99

Alopecia areata

-

1 (100)

-

0.44

Psoriasis

-

11 (91.7)

1 (8.3)

0.001

Urticaria

3 (75.0)

1 (25.0)

-

0.63

Acne rosacea

5 (55.6)

3 (33.3)

1 (11.1)

0.73

Contact dermatitis

2 (11.8)

10 (58.8)

5 (29.4)

0.32

Acanthosis nigricans

-

-

2 (100)

0.51

Localized hyperpigmentation

-

-

2 (100)

0.51

Age, years, mean (SD)
Sex, n (%)

Skin findings, n (%)

edema (100.0% vs. 0.0%, P = 0.04) among hypothyroid
patients. A significantly lower percentage of patients
with autoimmune than nonautoimmune thyroid disease
had xerosis (20.9% vs. 79.1%, P = 0.006) in the case of
euthyroid status (Table 2).
4. Discussion
Our findings in a cohort of patients with thyroid disease
and healthy control subjects revealed positive skin
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findings in 81.0% of thyroid disease patients and in 57.0%
of control subjects. The presence of autoimmune thyroid
disease was associated with a higher likelihood of skin
findings including alopecia, nail thinning, brittle nails,
diffuse hyperhidrosis, and flushing as compared with
nonautoimmune thyroid disease and normal thyroid
functions. There was a significantly higher percentage of
patients with autoimmune than nonautoimmune thyroid
disease among patients with onycholysis, yellow skin,

-

-

Acanthosis nigricans

Localized hyperpigmentation

3 (100)

Contact dermatitis

-

-

-

Urticaria

1 (100)

Psoriasis

Acne rosacea

-

-

Alopecia areata

3 (33.3)

2 (100)

-

-

-

-

-

6 (66.7)

-

-

Moist skin

-

Palmoplantar hyperkeratosis

1 (100)

-

-

-

4 (33.3)

1 (33.3)

1 (33.3)

5 (25)

5 (33.3)

Vitiligo

1 (100)

-

-

Carotenemia

Periorbital edema

-

Yellow skin

Diffuse edema

2 (66.7)

8 (66.7)

Facial erythema

2 (66.7)

Palmoplantar hyperhidrosis

Flushing

15 (75)

Diffuse hyperhidrosis

9 (42.9)

12 (57.1)

10 (66.7)

Xerosis

Pruritus

2 (11.1)

16 (88.9)

Brittle nails

2 (100)

2 (100)

-

2 (20)

Onycholysis

8 (80)

Nail thinning

-

Pitting

5 (100)

Hair dryness

4 (15.4)

0.09

-

-

-

-

0.99

-

-

0.99

-

0.32

0.99

-

-

0.92

0.96

0.96

0.39

0.90

0.18

0.02

0.09

0.45

0.31

0.16

0.01

0.03

16 (29.7)

38 (70.3)

22 (84.6)

Overall

Nonautoimmune P-value

Autoimmune

Alopecia

Skin findings
(+) n (%)

Hyperthyroid status
(n = 56)

-

-

4 (57.1)

1 (100)

1 (100)

8 (88.9)

1 (100)

1 (100)

2 (100)

6 (100)

1 (50)

8 (100)

3 (60)

9 (81.8)

11 (84.6)

7 (100)

3 (100)

8 (80)

25 (75.8)

45 (66.2)

24 (75)

2 (50)

6 (85.7)

20 (90.9)

11 (91.7)

29 (69)

91 (67.4)

Autoimmune

-

-

3 (42.9)

-

-

1 (11.1)

-

-

-

-

1 (50)

-

2 (40)

2 (18.2)

2 (15.4)

-

-

2 (20)

8 (24.2)

23 (33.8)

8 (25)

2 (50)

1 (14.3)

2 (9.1)

1 (8.3)

13 (31)

44 (32.6)

Nonautoimmune

Hypothyroid status
(n = 158)

Table 2. Skin findings in patients with autoimmune or nonautoimmune thyroid disease with respect to thyroid status.

-

-

0.68

0.99

0.99

0.27

0.99

0.99

0.99

0.17

0.54

0.04

0.65

0.50

0.17

0.09

0.55

0.50

0.26

0.71

0.32

0.59

0.43

0.01

0.10

0.83

0.83

P-value

-

-

3 (60)

2 (66.7)

-

2 (100)

-

1 (33.3)

-

-

1 (25)

-

-

2 (40)

5 (27.8)

1 (12.5)

-

2 (22.2)

9 (28.1)

9 (20.9)

5 (33.3)

-

1 (16.7)

3 (37.5)

7 (24.1)

25 (32.4)

Autoimmune

Euthyroid status
(n = 86)

-

-

2 (40)

1 (33.3)

-

-

-

2 (66.7)

1 (100)

-

3 (75)

3 (100)

3 (100)

3 (60)

13 (72.2)

7 (87.5)

6 (100)

7 (77.8)

23 (71.9)

37 (79.1)

10 (66.7)

2 (100)

1 (100)

5 (83.3)

5 (62.5)

22 (75.9)

52 (67.6)

Nonautoimmune

-

-

0.33

0.27

-

0.11

-

0.99

0.99

-

0.99

0.54

0.54

0.79

0.58

0.25

0.08

0.48

0.32

0.006

0.91

0.54

0.65

0.65

0.56

0.14

0.95

P-value
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periorbital edema, psoriasis, and palmoplantar keratosis
in the overall study population; among hyperthyroid
patients with overall skin findings, alopecia, and brittle
nails; and among hypothyroid patients with nail thinning
and periorbital edema.
In a past study conducted with Turkish patients with
thyroid disease (n = 220), skin findings were reported to be
detected in 56.8% of patients with chronic urticaria (6.8%),
vitiligo (6.8%), diffuse alopecia (6%), acne vulgaris (5%),
and acne rosacea (3.6%) as the most common findings (7).
In our study population 81.0% of patients had skin
findings with xerosis (45.0%), alopecia (32.3%), pruritus
(27.3%), brittle nails (22.0%), nail thinning (13.0%),
flushing (14.3%), and hair dryness (9.0%) as the most
commonly observed ones. When compared to controls, the
likelihood of alopecia, nail thinning, brittle nails, diffuse
hyperhidrosis, flushing, and xerosis was higher in thyroid
patients. Hence, our findings support the likelihood of
thyroid diseases to manifest with a wide range of changes
in the hair, skin, and nails depending on the thyroid status
and are in agreement with the positivity of skin findings
such as diffuse alopecia, xerosis, hyperhidrosis, soft and
friable nails, onycholysis, and pruritus reported in past
studies (3,5,7–11).
Xerosis is one of the characteristic cutaneous symptoms
in adults with hypothyroidism that has been considered to
occur as a result of peripheral cutaneous vasoconstriction,
hypohidrosis, and decline in epidermal sterol biosynthesis
and sebaceous gland secretion (2). Moreover, a potential
role for topical thyroid hormone has also been suggested
in the management of xerosis, even in patients with
euthyroidism (12). Hence, identification of xerosis as the
most common skin finding in our cohort of patients seems
consistent with the fact that 52.7% of overall patients were
hypothyroid and 28.7% were euthyroid.
None of our patients had thyroid acropachy,
pretibial myxedema, xhantoma, generalized myxedema,
bullous pemphigoid, or lupus erythematosus, along
with identification of vitiligo, alopecia areata, urticaria,
acne rosacea, acanthosis nigricans, and localized
hyperpigmentation in less than 1% of our patients.
Among the skin manifestations observed more
commonly in patient than in control groups in our
cohort, diffuse alopecia, nail thinning, and brittle nails are
more commonly associated with hypothyroidism (1,2),
while diffuse hyperhidrosis and flushing are among the
typical skin findings in hyperthyroid patients, attributed
to increased cutaneous blood flow and peripheral
vasodilation (13).
Diffuse alopecia and thyroid diseases have been
suggested to be associated in 60% of cases, mainly of
autoimmune origin (9–11). In a past study from Turkey
diffuse alopecia was noted in 6% of overall patients
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with thyroid disease, being higher in both autoimmune
hyperthyroidism and hypothyroidism patients when
compared to healthy controls (7). In our study population,
alopecia was the second most common skin finding in
overall patients, while among hyperthyroid patients with
alopecia, autoimmune rather than nonautoimmune origin
was more likely. This seems interesting given that alopecia
areata rather than diffuse alopecia was in fact associated
particularly with a history of atopy and autoimmune
disease (14–16).
Aside from alopecia areata, vitiligo and chronic urticaria
have also been considered among the dermatological
diseases associated with autoimmune thyroid disorders
(15,16). In a past study from Turkey, chronic urticaria,
vitiligo, and pruritus were reported to be significantly
more common among thyroid patients, while urticaria,
vitiligo, and diffuse alopecia were more common among
patients with autoimmune thyroid diseases as compared
with healthy control subjects (7). However, none of these
skin findings were more common in autoimmune than
in nonautoimmune disease in our cohort, and they were
observed in less than 1% of patients.
Nail changes are frequently encountered in
thyroid diseases with thin, striated, and brittle nails in
hypothyroidism and yellow nails in hyperthyroidism
as well as onycholysis in both conditions (3,5,8,9,17).
Accordingly, brittle nails were the most common thyroid
disease-related change in nails among our patients, and
like diffuse alopecia, among hyperthyroid patients with
brittle nails, autoimmune rather than nonautoimmune
origin of thyroid disease was more likely.
Being among the typical cutaneous manifestations of
autoimmune hypothyroidism and/or hyperthyroidism
(2), onycholysis, yellow skin, periorbital edema, psoriasis,
and palmoplantar keratosis were not observed among
control subjects, while they were more likely in the
case of autoimmune than nonautoimmune origin of
thyroid disease in our cohort. Based on the clinical and
biochemical overlap between Hashimoto’s thyroiditis
and Graves’ hyperthyroidism, the occurrence of the
same dermatologic and ophthalmologic manifestations
has been considered likely (8,10,18–21). Hence, our
findings seem to indicate that special emphasis should be
placed on skin manifestations of autoimmune etiologies
of hypothyroidism (i.e. Hashimoto’s thyroiditis) and
hyperthyroidism (i.e. Graves’ disease) (2,5,22).
Skin findings were observed in 96.4%, 85.4%, and
89.5% of our patients with hyperthyroid, hypothyroid,
and euthyroid status, respectively. Notably, there
were significantly higher percentages of patients with
autoimmune than nonautoimmune thyroid disease among
hyperthyroid patients with overall skin findings, alopecia,
and brittle nails and among hypothyroid patients with nail
thinning and periorbital edema.
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In contrast to our findings no statistical difference
was reported between “autoimmune vs. nonautoimmune”
hyperthyroidism, hypothyroidism, and euthyroidism in a
past study, while vitiligo and diffuse alopecia in patients
with autoimmune hyperthyroidism and vitiligo in patients
with autoimmune hypothyroidism were reported to be
higher as compared with the control group (7).
In this regard, our findings emphasize the higher
likelihood of certain cutaneous manifestations among
patients with autoimmune thyroid disease as compared not
only with controls but also with nonautoimmune thyroid
disease even in hyperthyroid and hypothyroid states.
Autoimmune thyroid diseases are frequently associated
with other organ-specific or systemic autoimmune
disorders (4), while both thyroid autoimmunity and
increased TSH were reported to represent independent
risk factors for thyroid malignancy (6). Hence, upon the
diagnosis of autoimmune thyroid disease, clinicians are
suggested to be vigilant for any of the potential associated
disorders for which the patient may be at risk throughout
the patient’s entire life (5,23).

Hyperthyroid patients had significantly higher
likelihoods of overall skin manifestations in the case of
autoimmune than nonautoimmune origin of thyroid
disease, while hypothyroid and euthyroid patients with
autoimmune thyroid disease showed higher prevalences of
only certain skin findings. Hence, our findings emphasize
the importance of recognizing cutaneous manifestations
and thus screening for thyroid autoimmunity and function
for early identification of thyroid dysfunction and potential
comorbidities when the thyroid disease is to be classified
as autoimmune, particularly among hyperthyroid patients.
In conclusion, our findings indicate the presence of skin
findings in a majority of thyroid patients, the prevalence
of which significantly differs for certain cutaneous
manifestations with respect to controls, autoimmune
etiology, and thyroid functional status. Early recognition of
cutaneous manifestations in thyroid patients, particularly
among patients with autoimmune hyperthyroidism, seems
to enhance timely screening for thyroid autoimmunity
and function and thus early identification of thyroid
dysfunction and potential comorbidities.
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